Sentences with phrase «pancreatic tumors in mice»

Not exact matches

One form of pancreatic cancer has a new enemy: a two - drug combination discovered by UF Health researchers that inhibits tumors and kills cancer cells in mouse models.

In the current study, Dr. Xu and colleagues gave radiation therapy to a mouse model of human pancreatic cancer to eradicate the bulk tumors, while only the cancer stem cells remained in the residual scarIn the current study, Dr. Xu and colleagues gave radiation therapy to a mouse model of human pancreatic cancer to eradicate the bulk tumors, while only the cancer stem cells remained in the residual scarin the residual scars.

In mice with pancreatic tumors, Kalbasi and other members of the team found relatively high levels of inflammatory compounds including CCL2, the signaling molecule that activates CCR2 on monocytes and macrophages to make these cells migrate to tumors.

The study, conducted in mice and including analyses of human cancers, found very high levels of two proteins — dectin - 1 and galectin - 9 — in pancreatic tumors.

Recently, teaming up with co-investigator Associate Professor Dr. Rolf A. Brekken, they looked into its possible involvement in Pancreatic Ductal Adenocarcinoma (PDA), the most common form of pancreatic cancer, in a mouse model with an early onset aggressive form of tumor dePancreatic Ductal Adenocarcinoma (PDA), the most common form of pancreatic cancer, in a mouse model with an early onset aggressive form of tumor depancreatic cancer, in a mouse model with an early onset aggressive form of tumor development.

In two mouse models of pancreatic cancer, a single treatment consisting of intravenous delivery of the PMILs followed by localized delivery of near - infrared light to the tumor site via optical fibers resulted in significantly greater reduction in tumor size than did either treatment with XL184 or PDT with BPD alonIn two mouse models of pancreatic cancer, a single treatment consisting of intravenous delivery of the PMILs followed by localized delivery of near - infrared light to the tumor site via optical fibers resulted in significantly greater reduction in tumor size than did either treatment with XL184 or PDT with BPD alonin significantly greater reduction in tumor size than did either treatment with XL184 or PDT with BPD alonin tumor size than did either treatment with XL184 or PDT with BPD alone.

With the help of various mouse models for pancreatic cancer, they have succeeded in elucidating the molecular pathways of tumor development in detail and have gained a better understanding of how various characteristics of the disease arise.

Meng and Nel also collaborated with Dr. Timothy Donahue, chief of gastrointestinal and pancreatic surgery and a Jonsson Comprehensive Cancer Center member, to demonstrate that treatment with the iRGD peptide can enhance tumor cell killing for patient - derived pancreatic cancers, growing subcutaneously in a mouse model.

The combination was significantly toxic to pancreatic cancer cells and disrupted tumor growth and extended survival in several types of advanced pancreatic cancer mouse models.

When antibodies and other methods were used to dramatically deplete the supply of Tregs in mice, the researchers saw a dramatic jump in the numbers of activated dendritic cells and CD8 + T cells in pancreatic tumor tissue, as well as a slowing of tumor growth.

In this study, samples were taken from patients» tumors during surgery and transplanted into mice to grow new pancreatic cancer tumors.

We chose this model because 1) it more closely recapitulates features of human pancreatic cancer than do s.c. - implanted tumors, 2) it can be used in immunocompetent mice to permit assessment of immune responses, and 3) the cells grow in vivo with predictable kinetics (34).

To evaluate tumor growth in mice of each genotype, we used an orthotopic implant model derived from a spontaneous pancreatic tumor arising in a C57BL / 6 KPC mouse (33), which expresses mutant forms of K - Ras and p53 selectively in pancreatic tissue.

The KPC1242 cell line, derived from a spontaneous pancreatic tumor that arose in a KPC mouse, was a generous gift of David Tuveson (Cold Spring Harbor Laboratories, Cold Spring, NY).

In a paper appearing online November 9, 2008 in the journal Nature, David Cheresh, Ph.D., professor and vice chair of pathology at the UC San Diego School of Medicine and the Moores UCSD Cancer Center and his co-workers mimicked the action of anti-angiogenesis drugs by genetically reducing VEGF levels in mouse tumors and inflammatory cells in various cancers, including pancreatic canceIn a paper appearing online November 9, 2008 in the journal Nature, David Cheresh, Ph.D., professor and vice chair of pathology at the UC San Diego School of Medicine and the Moores UCSD Cancer Center and his co-workers mimicked the action of anti-angiogenesis drugs by genetically reducing VEGF levels in mouse tumors and inflammatory cells in various cancers, including pancreatic cancein the journal Nature, David Cheresh, Ph.D., professor and vice chair of pathology at the UC San Diego School of Medicine and the Moores UCSD Cancer Center and his co-workers mimicked the action of anti-angiogenesis drugs by genetically reducing VEGF levels in mouse tumors and inflammatory cells in various cancers, including pancreatic cancein mouse tumors and inflammatory cells in various cancers, including pancreatic cancein various cancers, including pancreatic cancer.

To study how the modified virus attacks tumors, researchers in the McDonald lab injected it intravenously into mice genetically modified to develop neuroendocrine pancreatic cancer.

Bottom Line: Bacterial load was significantly higher in pancreatic tumor samples from patients with pancreatic ductal adenocarcinoma compared with pancreatic tissue from normal individuals, and in studies using mice, eliminating certain «bad» bacteria slowed the growth of pancreatic cancer, reversed immune suppression, and upregulated the immune checkpoint protein PD1.

This approach has led to the finding that activated fibroblasts in the tumor stroma mediate immune suppression in several mouse models of cancer, including the autochthonous model of pancreatic ductal adenocarcinoma of the Tuveson lab.